Jason S Slakter Selected Research

Verteporfin (Visudyne)

5/2012	Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
4/2009	Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
12/2007	Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study.
9/2007	Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.
9/2005	Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
4/2005	Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
4/2004	Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.
2/2004	Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
4/2003	Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
11/2002	Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason S Slakter Research Topics

Disease

32	Macular Degeneration (Age-Related Maculopathy) 01/2020 - 02/2002
22	Choroidal Neovascularization 01/2015 - 02/2002
6	Macular Edema 11/2016 - 03/2006
3	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2016 - 09/2006
3	Polypoidal Choroidal Vasculopathy 01/2015 - 10/2002
3	Central Serous Chorioretinopathy 07/2014 - 06/2003
3	Retinal Vein Occlusion 05/2011 - 03/2006
2	Geographic Atrophy 01/2021 - 01/2020
2	Endophthalmitis (Ophthalmia) 01/2020 - 10/2009
2	Hemorrhage 05/2011 - 02/2009
2	Inflammation (Inflammations) 11/2009 - 10/2009
2	Back Pain (Backache) 02/2004 - 10/2002
1	Vivax Malaria 01/2019
1	Edema (Dropsy) 09/2018
1	Neoplasms (Cancer) 09/2018
1	Retinal Detachment (Retinal Detachments) 09/2018
1	Hemangioblastoma 09/2018
1	Nausea 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Anorexia 01/2017
1	Diarrhea 01/2017
1	Fatigue 01/2017
1	Polyps 01/2015
1	Cicatrix (Scar) 09/2006
1	Contracture 09/2006
1	Retinal Perforations 09/2006
1	Telangiectasis (Telangiectasia) 09/2006
1	Choroidal Effusions 05/2005
1	Injection Site Reaction 02/2004
1	Myopia 04/2003
1	Pain (Aches) 02/2002

Drug/Important Bio-Agent (IBA)

12	Verteporfin (Visudyne)FDA Link 05/2012 - 02/2002
9	Fluorescein (Funduscein)FDA LinkGeneric 08/2013 - 02/2002
8	Ranibizumab (Lucentis)FDA Link 01/2015 - 09/2007
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018 - 11/2009
6	Bevacizumab (Avastin)FDA Link 09/2018 - 03/2006
6	afliberceptIBA 11/2016 - 11/2009
6	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2015 - 06/2003
6	anecortave acetateIBA 09/2006 - 02/2003
5	Retinaldehyde (Retinal)IBA 09/2018 - 10/2002
5	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2012 - 04/2004
2	pegcetacoplanIBA 01/2021 - 01/2020
2	Angiogenesis InhibitorsIBA 12/2003 - 02/2003
1	Complement Inactivating AgentsIBA 01/2021
1	Complement C3 (C3 Complement)IBA 01/2020
1	tafenoquineIBA 01/2019
1	SteroidsIBA 09/2018
1	Tyrosine Kinase InhibitorsIBA 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	Alanine Transaminase (SGPT)IBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2014
1	cadherin 5IBA 07/2014
1	Proteins (Proteins, Gene)FDA Link 11/2009
1	Immunoglobulin G (IgG)IBA 11/2009
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2009
1	Pharmaceutical PreparationsIBA 01/2006

Therapy/Procedure

13	Photochemotherapy (Photodynamic Therapy) 05/2012 - 02/2002
9	Therapeutics 12/2018 - 02/2002
5	Intravitreal Injections 09/2018 - 03/2006
5	Lasers (Laser) 09/2018 - 09/2006
4	Injections 01/2017 - 10/2009
3	Light Coagulation 11/2016 - 09/2006
3	Radiotherapy 01/2015 - 09/2013
2	Brachytherapy 08/2013 - 02/2013
1	Drug Therapy (Chemotherapy) 09/2018
1	Aftercare (After-Treatment) 09/2018
1	Retreatment 02/2013
1	Intraocular Injections 11/2009